Purpose: In vivo and in vitro observations strongly suggest that marked differences exist in the phenotype, growth, and matrix-producing capabilities of distinct smooth muscle cell subpopulations. An earlier study from our laboratory showed differences in matrix metalloproteinase expression patterns in cultures of medial smooth muscle cells from tissue affected by abdominal aortic aneurysm (AAA) or atherosclerotic occlusive disease and from normal arterial tissue. In this study we were interested in ascertaining whether smooth muscle cells from the same sample groups also synthesized different proteoglycan profiles that correlated with vascular disease. Methods: Proteoglycans from smooth muscle cell monolayer cultures from tissue affected by AAA or atherosclerotic occlusive disease and from normal arterial tissue were examined by means of immunoblotting and affinity-blotting composite agarose polyacrylamide gel electrophoresis (CAPAGE) and sodium dodecyl sulphate PAGE. Enzymelinked immunosorbent assay (ELISA) was used to quantitate perlecan levels in smooth muscle cell monolayer media samples. Results: Versican, perlecan, and biglycan levels were significantly elevated in AAA smooth muscle cell cultures. Two populations of smooth muscle cell versican were identified by means of CAPAGE-immunoblotting and by means of a novel affinity-blotting technique with biotinylated hyaluronan. A small keratan sulfate-substituted proteoglycan was present in similar levels in all smooth muscle cell cultures. This proteoglycan had a free core protein of about 55 kd after keratanase digestion and had a relatively high charge-tomass ratio, as was evident from its electrophoretic mobility in CAPAGE; this proteoglycan was tentatively identified as keratocan. Immunoblotting with monoclonal antibodies 3-G-10 (anti-∆ heparan sulfate, heparan sulfate stubs generated by heparitinase treatment) and 10-E-4 (anti-native heparan sulfate chains) helped identify several smooth muscle cell heparan sulfate-substituted proteoglycans. Elevated levels of intact and processed perlecan core protein were identified in AAA cultures by means of immunoblotting with a monoclonal antibody to perlecan core protein (A76). ELISA measurements confirmed that perlecan levels were significantly higher in AAA smooth muscle cell cultures compared with the normal arterial tissue and tissue affected by atherosclerotic occlusive disease. 
Proteoglycans are minor components of the normal arterial wall, but their accumulation in intimal lesions of blood vessels is a typical event in the early phases of atherosclerotic occlusive disease and abdominal aortic aneurysm (AAA) development. [1] [2] [3] Arterial proteoglycans can interact with a number of extracellular matrix macromolecules that influence arterial viscoelasticity, permeability, lipid accumulation, hemostasis, and thrombosis. 1, [3] [4] [5] Smooth muscle cells synthesize several heparan sulfatesubstituted, 6 -10 chondroitin sulfate-substituted, [11] [12] [13] and dermatan sulfate-substituted 2, 14 proteoglycans. These include the transmembrane syndecan family, 7 interstitial-extracellular matrix heparan sulfate-rich and chondroitin sulfate-rich proteoglycans perlecan and versican, 10, 12, 14 and the dermatan sulfate-rich proteoglycan biglycan. 14 The heparan sulfate proteoglycans (syndecan, perlecan) can act as low-affinity receptors for basic fibroblast growth factor (FGF), which may regulate the availability of this growth factor in the vessel wall. [15] [16] [17] [18] Biglycan is a small, leucine-rich repeat proteoglycan that contains two dermatan sulfate chains. 19 It has a cell surface and pericellular localization, but its exact function in the vessel wall is unknown. Biglycan can bind and thus control the bioavailability of transforming growth factor β and inhibit fibrillogenesis of type I collagen (the most abundant collagen in the vessel wall) in vitro. 20, 21 Thus it may control matrix accumulation and organization, processes relevant to the pathobiologic process of AAA and atherosclerotic occlusive disease. Versican has been shown to accumulate in intimal lesions of atherosclerotic vessels and is implicated in the entrapment of low-density lipoprotein in the arterial wall during atherogenesis. 4, 13 Although arterial proteoglycans are quantitatively minor structural components of the vessel wall, they may influence its physicochemical properties. This study was undertaken to compare proteoglycans synthesized by smooth muscle cells of persons with AAA or atherosclerotic occlusive disease and of normal media to determine whether variations in these proteoglycans can be correlated with disease processes in the vessel wall.
METHODS

Materials.
Materials were obtained from the sources indicated in an earlier publication, except where noted. 22 Dulbecco's modified Eagles medium (DMEM; high glucose and pyruvate containing L-glutamine) was purchased from Gibco BRL, Sydney, Australia. The anti-native heparan sulfate (clone F48-10-E-4), 8 anti-∆ heparan sulfate (clone 3-G-10), 8 JOURNAL OF VASCULAR SURGERY Volume 28, Number 4 Melrose et al 677 anti-keratan sulfate (clone 5-D-4), 23 monoclonal antibodies, and heparitinase (Flavobacterium heparinum) were purchased from the Seikagaku Corp., Tokyo, Japan. Antibodies LF-51 and LF-99 24 Patients and tissue specimens. All tissue harvesting and laboratory procedures were approved by the medical research ethics committee of the Royal North Shore Hospital (ethics no. 9501-02M). Specimens were obtained with informed consent. Specimens of AAA (n = 6) were obtained from the anterior infrarenal aortic wall at the time of operative AAA repair (median age 66 years, range 48 to 83 years). Specimens of atherosclerotic occlusive disease (n = 5) were obtained from the anterior infrarenal aortic wall from patients undergoing operative bypass for aortic occlusive disease (median age, 54 years; range, 45 to 63 years). Normal arterial tissue (n = 5) macroscopically free of atheroma was obtained from inferior mesenteric arteries within 3 cm of their insertion in the infrarenal aorta from patients undergoing left hemicolectomy for rectal cancer (median age, 57 years; range, 46 to 85 years). All patients in the study were men.
Culture of smooth muscle cells. Surgical specimens were transported in ice cold, sterile phosphatebuffered saline solution to the laboratory, where the medial arterial tissues were dissected free of intima and adventitia in a laminar flow hood and diced into 1 × 1 mm 3 cubes. Medial explants were cultured at 37°C in DMEM supplemented with 10% fetal calf serum under an atmosphere of 5% CO 2 in air and were maintained at 95% humidity. The smooth muscle cells that grew out of the explants were established as monolayer cultures. Once confluent, the smooth muscle cell monolayers were trypsinized and subpassaged. Smooth muscle cells from the fifth passage were seeded at a density of 2.5 × 10 5 per 25 cm 2 in canted neck flasks in 5 ml of DMEM/10% fetal calf serum medium. The smooth muscle cells were fed every 48 hours, and the media were collected for examination of their constituent proteoglycans. October 1998 Confirmation of smooth muscle cell phenotype by means of immunofluorescence microscopy. To confirm the smooth muscle cell phenotype, monolayer cells in their fifth passage were allowed to attach to glass coverslips for 3 days. They were then fixed in ice cold acetone, air dried, and incubated for 1 hour at room temperature with a 1/500 dilution of anti-smooth muscle cell α-actin monoclonal antibody. The coverslips were then washed in phosphatebuffered saline solution, and a 1/200 dilution of goat anti-mouse IgG fluorescein isothiocyanate-conjugated secondary antibody was added for 30 minutes at room temperature. The samples were washed again, and the coverslips were mounted on microscope slides and examined under epifluorescent illumination with a Leica MPS-60 fluorescent microscope.
Purification of media proteoglycans from monolayer culture of smooth muscle cells. Media samples were precipitated overnight at 4°C with 3 volumes of absolute ethanol, collected by means of centrifugation (800g for 10 minutes), redissolved overnight in 8 mol/L urea, 10 mmol/L 2-amino-2-(hydroxymethyl)-1, 3-propanediol (TRIS) acetate at pH 6.3, and 0.15 mol/L NaCl, and applied to a column of diethylaminoethyl (DEAE) sepharose CL6B. The column was washed with 4 bed volumes of starting buffer to remove nonbound material, and the bound proteoglycans were eluted with 4 mol/L GuHCl, 50 mmol/L TRIS HCl at pH 7, dialyzed against distilled water, and freeze dried.
Composite polyacrylamide agarose gel electrophoresis of smooth muscle cell proteoglycans. Slab gels (0.15 × 14 × 14 cm) of 0.6% agarose 1.2% acrylamide were cast in 10 mmol/L TRIS acetate pH 6.3 buffer containing 0.25 mmol/L sodium sulfate. 22 Proteoglycan samples (1.0 µg hexuronic acid/10 µL per well) were subjected to electrophoresis in 10 mmol/L TRIS acetate running buffer at pH 6.3 containing 1 mmol/L sodium sulfate at 150 volts for 2 hours. 22 The gels were either stained for 30 minutes in a solution of 0.02% weight/vol toluidine blue in 0.1 mol/L acetic acid or electroblotted to nitrocellulose membranes.
Immunoblotting and affinity blotting. Composite agarose polyacrylamide gel electrophoresis (CAPAGE) gels were blotted to nitrocellulose membranes in 25 mmol/L TRIS, 192 mmol/L glycine transfer buffer at pH 8.3 in a Bio-rad transblot semidry transfer cell at 5.5 mA/cm 2 constant current for 30 minutes. 22 The blots were blocked 3 hours in either 0.1% vol/vol polyoxyethylene (20) 22 or 5% weight/vol low-fat skim milk in 50 mmol/L TRIS HCl at pH 7.4, 0.15 mol/L NaCl and 0.02% weight/vol NaN 3 (immunoblots). Selected blots (LF-51, LF-99) were predigested overnight with chondroitinase ABC (0.025 units/mL) in 5% weight/vol skim milk in 50 mmol/L TRIS HCl at pH 7.2 containing 0.15 mol/L NaCl, 0.03 mol/L sodium acetate, and 0.02% weight/vol sodium azide. This digestion step also acted as a blocking step for the membrane. The primary reagents, that is, antibodies (5-D-4, A76) or bHA 22 (Table I) were applied in either TBS 0.05% Tween 20 (TBS-Tween) or 20 mmol/L TRIS HCl at pH 7.4 containing 0.1 mol/L NaCl (3-G-10, 10-E-4, LF-51, LF-99) and allowed to bind for 1 hour. The blots were then washed in the same buffer and incubated with an appropriate alkaline phosphataseconjugated secondary antibody (1/1000 dilution) or avidin-labeled alkaline phosphatase conjugate (0.5 µg/mL) for 1 hour. After washing, a solution of nitro blue tetrazolium/bromo-choroindolyl phosphate in alkaline phosphatase assay buffer was added for the visualization step. Selected blots were subjected to densitometric scanning with ScanAnalysis software (Biosoft, Cambridge, United Kingdom, Ferguson, Mo) to semiquantitate particular proteoglycan bands.
Perlecan enzyme-linked immunosorbent assay. Tenfold serial dilutions of affinity-purified human umbilical artery endothelial cell (HUAEC) perlecan (1 µg to 0.01 pg/well) and tenfold concentrated purified smooth muscle cell media proteoglycan samples (0.1 mL/well) in 20 mmol/L sodium carbonate buffer at pH 9.5 were allowed to bind overnight to Immulon 4 (DynaTech) microtiter immunoassay plates. The plates were then blocked for 5 hours with 1% weight/vol BSA in 25 mmol/L TRIS HCl at pH 7.2 containing 0.15 mol/L NaCl, 0.05% vol/vol Tween 20 and 0.02% weight/vol sodium azide (TBS-Tween; 0.25 mL/well). The plates were washed five times with TBS-Tween.
Anti-perlecan A76 monoclonal antibody (1 µg/mL) was added (0.1 µL/well) and allowed to bind for 3 hours at room temperature. The plates were washed again, and secondary antibody, a 1/1000 dilution of alkaline phosphatase-labeled anti-mouse IgG (0.2 mL/well) was added. After 1 hour at room temperature for binding, the plates were washed again, and a solution of Sigma 104 alkaline phosphatase substrate (1 mg/mL) in 0.1 mol/L TRIS HCl buffer at pH 9.5 was added. Color development was allowed to proceed for up to 12 hours at 37°C. The plates were read at A405 nm with an automatic plate reader. A binding curve was constructed with the perlecan standard data, and levels of perlecan in the purified smooth muscle cell media proteoglycan samples were calculated from this calibration curve. The data were normalized on the basis of the number of cells in culture. Assay Zap version 2.0 software (Biosoft) was used for curve interpolation on a Macintosh LC personal computer.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting of smooth muscle cell media proteoglycans. Samples of anion exchange purified smooth muscle cell media proteoglycans were redissolved in the appropriate buffer for particular predigestion protocols (see later) then subjected to electrophoresis on 4% to 12% polyacrylamide gradient gels in TRIS-glycine buffer according to the method of Laemmli. 25 Samples of smooth muscle cell media proteoglycans were predigested with keratanase (0.1 U/mg dry weight proteoglycan) in TRIS-acetate buffer at pH 7.4 with heparitinase (10 mU/mg dry weight proteoglycan) in 50 mmol/L sodium HEPES solution at pH 7.0 containing 100 mmol/L NaCl, 1 mmol/L benzamidine, 1 mmol/L 6-amino hexanoic acid, 1 mmol/L ethylenediamenetetraacetic acid (EDTA), and 2 mmol/phenylmethyl sulfenyl fluoride for 3 hours at 37°C. Smooth muscle cell proteoglycan samples were subjected to electrophoresis at 125V for 90 minutes then electroblotted to nitrocellulose and blocked overnight in 5% weight/vol skim milk. The blots were probed with either 1/1000 dilution 5-D-4, 1/1000 10-E-4, 1/1000 3-G-10, 1/1000 anti-versican or 2 µg/mL A76 anti-perlecan primary antibodies. The blots were then developed with appropriate secondary antibodies as indicated earlier and in Table I with NBT/BCIP as substrate. Novex molecular weight standards and affinity purified HUAEC perlecan (with or without heparitinase predigestion) standards also were subjected to electrophoresis.
RESULTS
Immunofluorescence microscopic examination readily demonstrated the presence of smooth muscle cell α-actin in cytoskeletal elements in all of the AAA, arterial occlusive disease, and normal smooth muscle cell monolayer cultures, more than 99% of all cells stained positively for the presence of smooth muscle cell α-actin, and a hill and valley structure typical of smooth muscle cells was evident (data not shown).
Examination of smooth muscle cell media proteoglycans by means of CAPAGE demonstrated several proteoglycan species of differing mobilities in this native electrophoretic system (Fig 1) . Three of these proteoglycan species had faster mobilities than the major chondroitin sulfate-substituted and keratan sulfate-substituted aggrecan populations present in ovine articular cartilage, demonstrating that they were of higher charge-to-mass ratios. Two of the smooth muscle cell proteoglycan species were of similar mobility to the dermatan sulfate-substituted proteoglycans of articular cartilage, decorin and biglycan. Little difference was demonstrated between the normal and arterial occlusive disease smooth muscle cell media proteoglycan samples in the CAPAGE system (Fig 1) . However, the fastest migrating smooth muscle cell proteoglycan species, which had a mobility greater than the cartilage dermatan sulfate proteoglycans and a similar mobility to the 36-kd chondroitin sulfate standard (Fig 1) , was largely undetectable in the AAA media samples after day 3 in culture but was present on all days of culture in the normal and arterial occlusive disease samples (Fig 1) . This species represented a mixture of free glycosaminoglycan chains and a proteoglycan species of high charge-to-mass ratio, which was substituted with heparan sulfate (Fig 2, B) . Smooth muscle cell media proteoglycans were examined by means of affinity blotting with bHA to detect proteoglycan populations containing a domain capable of interacting with hyaluronan ( Fig  3) . Correlations with immunoblotting data obtained with an antibody to human versican core protein were established (Fig 3) . On day 3 versican expression was readily detectable by means of immunoblotting in the AAA samples (Fig 3) but was only just detectable in the normal and arterial occlusive disease samples (Fig 3) . Versican expression was detectable in all samples on day 7 but was strongest in the AAA sample. Two species of slightly different mobilities and hence of differing charge-to-mass ratios were evident (Fig 3, V-1 and V-2) . The normal and arterial occlusive disease smooth muscle cell versican species detected was of the same mobility as the least mobile AAA versican species (V-1) and was of similar mobility to a fibroblast media proteoglycan (versican) sample (Fig 3) . Smooth muscle cell versican detected by means of affinity and immunoblotting after CAPAGE was of lower mobility than cartilage aggrecan, which was run as an internal standard (Fig 3) . This finding was consistent with the known structure of versican, which is less heavily substituted with glycosaminoglycan but contains a relatively large core protein compared with aggrecan and is of lower charge-to-mass ratio and would be predicted to be of lower mobility in the CAPAGE system. Immunoblotting helped confirm the identity of the hyaluronan-binding proteoglycans detected with bHA as versican. Both AAA versican isoforms were detected (Fig 3) .
Immunoblotting of the smooth muscle cell proteoglycans with a monoclonal antibody to human perlecan (A76) demonstrated that perlecan levels were higher in the AAA media sample compared with arterial occlusive disease and normal smooth muscle cell proteoglycan samples (Fig 2, A) . Densitometric scanning indicated that perlecan levels were threefold to sixfold higher in the AAA sample compared with the arterial occlusive disease or normal smooth muscle cell samples examined. HUAEC perlecan deglycosylated by means of predigestion with heparitinase was of lower mobility in the CAPAGE system compared with its native counterpart (Fig 2, A) . Heparan sulfate-substituted smooth muscle cell proteoglycan species were identified with a monoclonal antibody to heparan sulfate 10-E-4 (Fig 2, B) . Densitometric scanning indicated that levels of the heparan sulfate proteoglycans were higher in the AAA compared with arterial occlusive disease or normal samples. Two to three heparan sulfate proteoglycan species were present in the AAA smooth muscle cell media samples (Fig 2, B) . Two of the smooth muscle cell heparan sulfate-substituted proteoglycan species were of similar mobility to HUAEC perlecan in the CAPAGE system (Fig 2, A and B) . Biglycan was detected in the smooth muscle cell media samples by means of immunoblotting (Fig 2, C) . Densitometric scanning of the blot indicated that the AAA sample contained threefold to fourfold higher levels of biglycan than the arterial occlusive disease or normal samples (Fig 2, C) . A keratan sulfate-substituted proteoglycan species also present in all smooth muscle cell media samples; however, it was present in similar levels in all smooth muscle cell samples examined. This keratan sulfate proteoglycan was of considerably higher mobility in CAPAGE than the two aggrecan populations of cartilage (Fig 2, D) . The native form of this keratan sulfate-substituted proteoglycan and its free core protein were demonstrated by means of 4% to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) with or without keratanase predigestion and immunoblotting with mon- Table I oclonal antibody 5-D-4 (anti-keratan sulfate) to be about 100 to 250 kd (Fig 4, A) and about 55 kd, respectively (Fig 4, B) .
Enzyme-linked immunosorbent assay (ELISA) of media perlecan confirmed that AAA smooth muscle cell cultures contained higher levels of perlecan than the normal or arterial occlusive disease smooth muscle cells (Fig 5) . AAA smooth muscle cell cultures contained 14.2 ± 3 ng perlecan per 1000 cells in culture on day 1. This increased to 26.3 ± 4 ng per 100,000 cells on day 7. Normal and arterial occlusive disease media samples contained significantly lower levels of perlecan (5.2 to 7.4 ng/100,000 cells and 5.3 to 9.7 ng/100,000 cells, respectively).
Examination of the smooth muscle cell media proteoglycans by means of 4% to 12% SDS PAGE followed by immunoblotting with monoclonal antibodies reactive with heparan sulfate (MAb 10-E-4) and with the unsaturated stub epitopes generated by means of the action of heparitinase on the heparan sulfate side chains of heparan sulfate-substituted proteoglycans (MAb 3-G-10) provided information regarding the size of the intact smooth muscle cell heparan sulfate proteoglycan species and their core proteins (Fig 6) . The AAA smooth muscle cell media proteoglycan samples clearly differed from the normal and arterial occlusive disease samples in terms of the species identified with the aforementioned monoclonal antibodies (Fig 6) . Use of MAb 10-E-4 also helped detect a prominent proteoglycan species of 200 to 250 kd in the AAA samples, which was not detected with Mab A76 (Fig 6) . This species possibly represented a 250-kd heparan sulfate-substituted basement membrane proteoglycan unrelated to perlecan. 27, 28 Use of MAb 3-G-10 helped detect two prominent small core protein proteoglycan species of about 38 and 45 kd in the AAA sample (Fig 6) . These also were detected with Mab A76 (Fig 6) and thus appeared to be amino terminal fragments of perlecan core protein. A range of heparan sulfate-substituted proteoglycan species were evident in the AAA samples (Fig 6) . Most of these also were detected with Mab A76 (Fig 6) , suggesting that the perlecan core protein had been extensively degraded in the AAA monolayer cultures.
DISCUSSION
Several laboratories have demonstrated that arterial smooth muscle cell subpopulations with unique biochemical and growth properties can be cultured in monolayers with preservation of these characteristics over multiple passages. [29] [30] [31] Because isolated smooth muscle cell subpopulations do not converge into a common phenotype in monolayer culture, it would appear that the observed in vitro cellular diversity is attributable to an intrinsic heterogeneity in arterial smooth muscle cells rather than to phenotypic modulation of smooth muscle cells under culture conditions. An earlier study from our laboratories suggested that AAA and arterial occlusive disease are quite distinct disease processes in terms of matrix metalloproteinase expression patterns. 32 It was logical to extend these earlier observations by using the monolayer culture system to further assess whether differences were evident in the phenotypic expression of matrix components by smooth muscle cells derived from AAA arterial occlusive disease or normal arterial tissue.
The results obtained in this study clearly showed that AAA smooth muscle cells produced qualitatively higher levels of perlecan (and another unidentified 250-kd heparan sulfate-substituted proteoglycan), versican, and biglycan in monolayer culture than did normal or arterial occlusive disease smooth muscle cells (Figs 2 through 5 ). This supports our earlier contention that smooth muscle cells from AAA and arterial occlusive disease tissues display differing phenotypes in vitro. 32 Nikkari et al. 32 also demonstrated elevated transcript levels for perlecan, syndecan, and versican 2 to 4 weeks after injury in a rat carotid artery balloon injury model. This study also showed that versican synthesized by smooth muscle cell monolayers is capable of interacting with hyaluronan by means of affinity blotting. This is the first such study to use this technique 22 to demonstrate that smooth muscle cells synthesize aggregatable versican in monolayer culture (Fig 3) .
Two versican isoforms were synthesized by the AAA smooth muscle cells and were identified by means of immunoblotting (Fig 3) . These may represent versican isoforms of differing glycosylation patterns or proteolytically processed forms.
CAPAGE is a system extensively used for analysis of aggrecan species in normal and diseased cartilaginous tissues. 22 In this study we have applied the CAPAGE system for analysis of the large smooth muscle cell proteoglycans perlecan and versican. This technique offers some advantages over conventional SDS PAGE for analysis of proteoglycans with extremely large core proteins (such as versican and perlecan) or extensive hydrodynamic domains resulting from extensive glycosaminoglycan substitution patterns. To the best of our knowledge this is the first time this separation technique has been applied to the analysis of versican and perlecan.
Cell-associated heparan sulfate proteoglycans such as the syndecan family and perlecan interact with growth factors such as FGF-2, vascular endothelial cell growth factor, and epidermal growth factor. [34] [35] [36] This interaction between heparan sulfate and a respective growth factor is essential for expression of its biologic activity. Thus FGF-2 must first bind to heparan sulfate on the cell surface before it can bind to tyrosine-kinase-FGF receptors that elicit the FGF-2 response on target cells. 35 Induction of smooth muscle cell surface heparan sulfate proteoglycans can therefore trigger cellular behavior such as proliferation and migration caused by the ability of the heparan sulfate proteoglycans to bind and thus augment the action of heparin-binding growth factors such as FGF-2, heparin-binding epidermal growth factor, and platelet-derived growth factor. An earlier study from our laboratory demonstrated that smooth muscle cells from medial AAA tissue has greater proliferative capacity in outgrowth cultures than smooth muscle cells of normal or arterial occlusive disease tissues. 37 The results of this study, which demonstrated an elevation in synthesis of heparan sulfate proteoglycans by AAA smooth muscle cells in culture, therefore are consistent with this interpretation. Moreover, our laboratory and others have shown that AAA cells secrete significantly higher levels of matrix metalloproteinase-2 and matrix metalloproteinase-9 than smooth muscle cells from normal or arterial occlusive disease specimens. [38] [39] [40] [41] [42] Halpert et al. 43 showed that matrix metalloproteinases secreted by macrophages were localized to areas of versican deposition in atherosclerotic lesions. This finding suggested that the versican was acting as an in situ substrate for matrix metalloproteinases.
The AAA smooth muscle cell cultures in this study expressed elevated levels of versican (Fig 3) , this was present as two forms of differing charge-to-mass ratios, which may have arisen from endogenous cleavage of versican core protein. Fragments of perlecan also were identified in AAA cultures (Fig 6) . Two small ∆-heparan sulfate-substituted perlecan core protein fragments were prominent in the AAA cultures and were both detected with Mab A76 and Mab 3-G-10 (Fig 6) . These fragments must have arisen from the amino terminus of the perlecan core protein, unlike carboxyl terminal V-8 protease resistant perlecan core protein fragments, which also have been described. 44 This suggests that an A76 binding epitope is present within the amino terminal heparan sulfate-substituted region of the perlecan core protein.
The presence of multiple core protein species in the AAA smooth muscle cell media samples indicates endogenous proteolysis of matrix proteoglycans such as perlecan and versican in the monolayer cultures. Such a proposal is appealing, because proteolysis of smooth muscle cell heparan sulfate proteoglycans in situ might result in localized release of a range of mitogenic growth factors capable of influencing synthesis of the matrix metalloproteinases and their endogenous inhibitory proteins. 18, 45 Such a process might account for both the greater proliferative capacity and the elevated matrix metalloproteinase expression displayed by AAA smooth muscle cells in vitro.
In summary, this study demonstrated a differential relationship between proteoglycan species synthesized by smooth muscle cells from AAA, arterial occlusive disease, and normal medial vessel tissues. In general, the levels of perlecan, versican, and biglycan synthesized by AAA smooth muscle cells in monolayer culture were significantly higher than synthe- Demonstration of heparan sulfate-substituted proteoglycan species in smooth muscle cell media samples from day 7 of passage 5. Anion exchange-purified smooth muscle cell media proteoglycans were subjected to electrophoresis on 4% to 12% SDS PAGE gels and electroblotted to nitrocellulose. Selected samples were predigested with heparitinase before this step. Heparan sulfate proteoglycan species were identified on immunoblots with the following monoclonal antibodies: mouse anti-human perlecan core protein (A76); anti-native heparan sulfate (10-E-4), and anti-∆-unsaturated heparan sulfate stub epitopes generated by means of the action of heparitinase on the heparan sulfate side chains of heparan sulfate proteoglycan species.
